Table 1. NS indicates not significant.... | American Society of Hematology

Table 1.

$Rituximab-based salvage therapy in relapsing/refractory DLBCL$

NS indicates not significant.

*Plus RIT at bulky disease.

†The choice of conditioning regimen depended on physician decision and the clinical trial.